Table 2.
The PEDro quality scores for the included literature.
| Items | Wang[14] 2022 | Wang[20] 2023 |
Chen[21] 2023 |
Xie[22] 2021 | Liao[23] 2020 |
Li[24] 2021* |
Koch [15] 2019 | Lin[25] 2019 |
|---|---|---|---|---|---|---|---|---|
| Eligibility criteria | Y | Y | Y | Y | Y | Y | Y | Y |
| Random allocation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Concealed allocation | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Baseline comparability | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Blinded subjects | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| Blinded therapists | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| Blinded assessors | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| Adequate follow-up (>85%) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Intention-to-treat analysis | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Between-group comparisons | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Point estimates and variability | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total PEDro score | 6 | 5 | 8 | 10 | 9 | 5 | 9 | 6 |
| Level of quality | H | M | H | H | H | M | H | H |
| Sample size ≥ 50 | N | N | N | N | N | Y | N | N |
H = high quality (6–10 points), M = moderate quality (4–5 points).
*
Due to the outcome index data could not be extracted, this study was not included in the meta-analysis.